Warrants (Details) - USD ($) |
12 Months Ended | |||
---|---|---|---|---|
May 17, 2022 |
Aug. 24, 2016 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
Warrants [Line Items] | ||||
Estimated fair value | $ 145,000 | $ (1,658,000) | $ 1,049,000 | |
Other financial expenses (income) | (1,726) | 1,049,000 | ||
Comerica Warrants [Member] | ||||
Warrants [Line Items] | ||||
Estimated fair value | $ 8,000 | $ 8,000 | ||
Series B Redeemable Preferred Stock [Member] | ||||
Warrants [Line Items] | ||||
Purchase shares (in Shares) | 73,048 | |||
Exercise price per share (in Dollars per share) | $ 1.02672 |
X | ||||||||||
- Definition Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of other expense (income) that is infrequent in occurrence or unusual in nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|